Phenylketonuria due to phenylalanine hydroxylase deficiency: an unfolding story. Medical Research Council Working Party on Phenylketonuria.
Efficient neonatal screening for phenylketonuria and the availability of complex diets for lifelong use have virtually eliminated severe mental handicap from the disease. Nevertheless, there remains a high risk of fetal damage in offspring of women with the disease, and the possibility that the diets themselves may be harmful cannot be excluded. Search for a preventive treatment for the disease has been greatly aided by advances in molecular genetics. For example, in mice modified liver cells have been implanted, which have not only corrected the phenylalanine defect but have remained healthy for the normal life span of the animal. Overall, however, prevention and treatment have not progressed as quickly as was hoped, and research and development must be pursued vigorously to take account of contemporary perceptions of the disorder.
D000293:Adolescent; D000328:Adult; D000818:Animals; D002493:Central Nervous System Diseases / Q000209:etiology; D002648:Child; D005260:Female; D006301:Health Services Needs and Demand; D006801:Humans; D051379:Mice; D010651:Phenylalanine Hydroxylase / Q000172:deficiency* / Q000235:genetics*; D017042:Phenylketonuria, Maternal / Q000150:complications; D010661:Phenylketonurias / Q000150:complications / Q000235:genetics* / Q000628:therapy; D011247:Pregnancy; D006113:United Kingdom
D010651:Phenylalanine Hydroxylase